Treatment limitations imposed by antiretroviral drug resistance mutations: Implication for choices of first line regimens in resource-limited settings

HIV Medicine

Volumn 13, Issue 3, 2012, Pages 141-147

  Mtambo, A ^a,b   Chan, K ^b   Shen, A ^b   Lima, V ^b   Hogg, R ^a,b   Montaner, J ^b,c   Moore, D ^b,c  

^a SIMON FRASER UNIVERSITY   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; Boosted protease inhibitors; Drug resistance; Genotypic sensitivity scores; Nonnucleoside reverse transcriptase inhibitors; Resource limited settings

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84856579220     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00950.x     Document Type: Article

References (28)

1. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva: WHO library cataloguing, 2006.
2. Akileswaran C, Mark N, Timothy P, Mayer KH.Lessons learned from use of Highly Active Antiretroviral Therapy in Africa. Clin Infect Dis 2005; 41: 376-385.
3. Beck EJ, Marco V, Sundhiya Met al. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 2006; 20: 1497-1502.
4. Calmy A, Ford N, Hirschel Bet al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44: 128-134.
5. Ekong E, Akinlade O, Uwah Aet al. Comparative assessment of response to HAART of the elderly and young HIV/AIDS patients in a resource-limited setting. 15th International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract ThPeB7187].
6. Gandhi T, Nagappan V, Cinti Set al. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen. Clin Infect Dis 2007; 45: 1085-1092.
7. Harrigan PR, Hogg RS, Dong WWYet al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. JID 2005; 191: 339-347.
8. Pujades-Rodriguez M, O'Brien D, Hamblet Pet al. Second-line antiretroviral therapy in resource limited settings: the experiences of Medecins Sans Frontieres. AIDS 2008; 22: 1305-1312.
9. Hosseinipour M, Kumwenda J, Weigel Ret al. 2009 Clinical, immunological and virological outcomes of second-line treatment, Malawi. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract #605].
10. Fox M, Ive P, Malope-Kgokong Bet al. 2009 Clinical outcomes on second-line antiretroviral therapy in a large urban clinic in Johannesburg, South Africa. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract # 606].
11. Whitcomb JM, Parkin NT, Chappey Cet al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus Type 1 clinical isolates. JID 2004; 188: 992-1000.
12. Lima VD, Gill VS, Yip Bet al. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. JID 2008; 198: 1-8.
13. Riddler SA, Haubrich R, DiRienzo Get al. 2006 A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV infection-ACTG 5142. XVI International AIDS Conference. Toronto, Canada, August 2006 [Abstract THLB0204].
14. Dabis F, Balestre E, Braitstein P for the ART-LINC Study Group. Antiretroviral therapy in lower income countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005; 34: 979-986.
15. Krain A, Fitzgerald DW.HIV antiretroviral therapy in resource-limited settings: experiences from Haiti. Curr HIV/AIDS Rep 2005; 2: 98-104.
16. + cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med 2003; 139: 810-816.
17. Hogg RS, Yip B, Chan KJet al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568-2577.
18. BC CfE. Therapeutic guidelines: antiretroviral treatment of adult HIV infection, 2009. BC Centre for Excellence in HIV/AIDS. Available at (accessed 20 February 2009).
19. Hammer SM, Eron JJ, Reiss Pet al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA Panel. JAMA 2008; 300: 555-570.
20. DeGruttola V, Dix L, D'Aquila Ret al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using standardized data analysis plan. Antiviral Ther 2000; 5: 41-48.
21. UNAIDS. Drug Access Initiative - price list. Ugandan Ministry of Health; 2006; Kampala, Uganda.
22. Ministry of Health, Zambia. Antiretroviral therapy for chronic HIV infection in adults and adolescents. Ministry of Health, Lusaka, Zambia. Available at (accessed 26 February 2009).
23. Ciaranello AL, Lockman S, Freedberg KAet al. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS J 2007; 25: 479-492.
24. World Health Organization. PMTCT Strategic vision 2010-2015. February 2010. Geneva, Switzerland. Available at
25. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomized phase 2/3 trial. Lancet Infect Dis 2011; 11: 273-283.
26. Moore RD, Kumar R.Outcomes of ritonavir-boosted protease inhibitor versus non-nucleoside reverse transcriptase regimens in a clinical practice cohort. J Antivir Antiretrovir 2010; 1: 13-19.
27. Nachenga JB, Hislop M, Dowdy DWet al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146: 564-573.
28. Soares MA. Drug resistance differences among HIV types and subtype: a growing problem. Future HIV Ther 2008; 2: 579-593.